Scientific goal: To improve cancer therapy through technology-driven research on the high-throughput characterization, computational modeling, and rational reprogramming of the cancer epigenome.
techniques and infrastructure of the research group:
• Epigenomics. We perform large-scale epigenome mapping to dissect the dynamics of drug resistance in cancer.
• Technology. Exciting biomedical research is often driven by new technologies. Our lab is therefore heavily invested into technology development, including single-cell assays, nanopore sequencing, CRISPR, and epigenome editing.
• Bioinformatics. New algorithms and advanced computational methods allow us to infer epigenetic cell states from large datasets, in order to reconstruct the epigenetic landscape of cellular differentiation and reprogramming.
• Diagnostics. Using large-scale DNA methylation mapping, bioinformatic prioritization, and functional characterization, we strive to develop clinically relevant biomarkers for informing personalized cancer therapy.
5 selected publications
1. Schmidl et al. (2015) Nature Methods & Farlik et al. (2015) Cell Reports & Tomazou et al. (2015) Cell Reports -- Experimental and computational methods for low-input / single-cell epigenome mapping and integrative analysis
2. Bock (2012) Nature Reviews Genetics -- Critical review of the state-of-the-art in the genome-wide analysis and interpretation of DNA methylation
3. Bock and Lengauer (2012) Nature Reviews Cancer -- Roadmap to personalized cancer therapy using rationally designed drug combinations (inspired by successes in personalized HIV therapy)
4. Assenov (2014) Nature Methods, Halachev (2012) Genome Biology, Lutsik (2011) Nucleic Acids Research, Schüffler (2009) Genome Biology, Bock (2009) Genome Biology, Bock (2005) Bioinformatics -- Development of widely used software tools for user-friendly analysis of DNA methylation data.
5. Bock et al. (2011) Cell -- Development of a computational scorecard for predictive diagnostics of stem cell quality in regenerative medicine.